- Apply guideline-concordant approaches for molecular testing in patients with HR+/HER2- metastatic breast cancer (MBC) across the disease continuum
- Evaluate recent real-world evidence providing practical insights into the use of targeted treatment strategies for HR+/HER2- MBC
- Integrate clinical trial and real-world data alongside patient- and disease-specific characteristics into personalized treatment decisions for patients with HR+/HER2- MBC
- Develop evidence-based strategies for monitoring and mitigating adverse effects associated with targeted therapies for HR+/HER2- MBC
Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer
May 6, 2026
5:15 PM - 6:30 PM PT
Virtual Regional Meeting | Nevada
Overview:
This live, virtual symposium will bring together a nationally recognized expert and a local thought leader to discuss key advancements in the management of endocrine-sensitive HR+/HER2- metastatic breast cancer (MBC), with a focus on treatment options following first-line endocrine therapy (ET) plus a CDK4/6 inhibitor. Through interactive discussions, participants will explore the role of mutational testing to guide therapy selection, and the efficacy and safety of next-generation targeted therapies, including oral SERDs and PI3K, AKT, and mTOR inhibitors. The program will also address best practices for managing adverse effects, using a case-based format to provide practical insights to improve patient care.
Learning Objectives:
Upon completion of this activity, participants will be able to:
Target Audience:
This educational program is primarily directed toward a global audience of community-based medical oncologists, advanced practice providers, nurses, and other healthcare providers involved in the treatment of metastatic breast cancer.
Accreditation/Credit Designation:
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.25 Contact Hours.
Acknowledgment of Educational Support
This activity is supported by an educational grant from Stemline Therapeutics, Inc.
Have a question for the PER® team?
Oncology Inquiries: onc-info@gotoper.com
Eye Care Inquiries: eye-info@gotoper.com
Multispecialty Inquiries: multi-info@gotoper.com
259 Prospect Plains Rd, Building H, Monroe, NJ 08831
Copyright ©2026
Physicians' Education Resource®, LLC.
All rights reserved
.png)